Palonosetron oral

Drug Profile

Palonosetron oral

Alternative Names: Aloxi Capsule

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharma Europe; Helsinn; Sinclair IS Pharma
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 May 2017 No recent reports on development identified - Registered for Chemotherapy induced nausea and vomiting (Prevention) in Iceland and Liechtenstein (PO)
  • 06 Mar 2015 No recent reports on development identified - Phase-III for Chemotherapy induced nausea and vomiting (Prevention) in India, Russia, Ukraine and Mexico (PO)
  • 17 Jul 2014 Oral palonosteron licensed to Chugai Pharma Europe in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top